{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T11:55:32Z","timestamp":1713786932048},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s40122-013-0011-1","type":"journal-article","created":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T04:12:40Z","timestamp":1366171960000},"page":"65-71","source":"Crossref","is-referenced-by-count":9,"title":["Interpreting Effect Sizes and Clinical Relevance of Pharmacological Interventions for Fibromyalgia"],"prefix":"10.1007","volume":"2","author":[{"given":"Lesley M.","family":"Arnold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph C.","family":"Cappelleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Clair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth T.","family":"Masters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,18]]},"reference":[{"key":"11_CR1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/art.1780330203","volume":"33","author":"F Wolfe","year":"1990","unstructured":"Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160\u201372.","journal-title":"Arthritis Rheum"},{"key":"11_CR2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1017\/S1092852900026778","volume":"13","author":"IJ Russell","year":"2008","unstructured":"Russell IJ, Raphael KG. Fibromyalgia syndrome: presentation, diagnosis, differential diagnosis, and vulnerability. CNS Spectr. 2008;13:6\u201311.","journal-title":"CNS Spectr"},{"key":"11_CR3","unstructured":"Eli Lilly and Company. Cymbalta\u00ae US prescribing information. Available at: http:\/\/pi.lilly.com\/us\/cymbalta-pi.pdf . Accessed 8 Feb 2013."},{"key":"11_CR4","unstructured":"Forest Pharmaceuticals. Savella\u00ae US prescribing information. Available at http:\/\/www.frx.com\/pi\/Savella_pi.pdf . Accessed 16 Jan 2013."},{"key":"11_CR5","unstructured":"Pfizer Inc. LYRICA\u00ae US prescribing information. Available at http:\/\/www.pfizer.com\/files\/products\/uspi_lyrica.pdf . Accessed 16 Jan 2013."},{"key":"11_CR6","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1002\/art.20485","volume":"50","author":"LM Arnold","year":"2004","unstructured":"Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50:2974\u201384.","journal-title":"Arthritis Rheum"},{"key":"11_CR7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.pain.2005.06.031","volume":"119","author":"LM Arnold","year":"2005","unstructured":"Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119:5\u201315.","journal-title":"Pain"},{"key":"11_CR8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.pain.2008.02.024","volume":"136","author":"IJ Russell","year":"2008","unstructured":"Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136:432\u201344.","journal-title":"Pain"},{"key":"11_CR9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2147\/IJGM.S3979","volume":"1","author":"AS Chappell","year":"2008","unstructured":"Chappell AS, Bradley LA, Wiltse C, Detke MJ, D\u2019Souza DN, Spaeth M. A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med. 2008;1:91\u2013102.","journal-title":"Int J Gen Med."},{"issue":"Suppl 1","key":"11_CR10","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1002\/hup.622","volume":"19","author":"O Vitton","year":"2004","unstructured":"Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol. 2004;19(Suppl 1):S27\u201335.","journal-title":"Hum Psychopharmacol"},{"key":"11_CR11","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.clinthera.2008.11.009","volume":"30","author":"DJ Clauw","year":"2008","unstructured":"Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther. 2008;30:1988\u20132004.","journal-title":"Clin Ther"},{"key":"11_CR12","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3899\/jrheum.080734","volume":"36","author":"PJ Mease","year":"2009","unstructured":"Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009;36:398\u2013409.","journal-title":"J Rheumatol"},{"key":"11_CR13","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3899\/jrheum.090884","volume":"37","author":"JC Branco","year":"2010","unstructured":"Branco JC, Zachrisson O, Perrot S, Mainguy Y. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. J Rheumatol. 2010;37:851\u20139.","journal-title":"J Rheumatol"},{"key":"11_CR14","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1002\/art.27559","volume":"62","author":"LM Arnold","year":"2010","unstructured":"Arnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y. Efficacy and safety of milnacipran 100\u00a0mg\/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62:2745\u201356.","journal-title":"Arthritis Rheum"},{"key":"11_CR15","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/art.20983","volume":"52","author":"LJ Crofford","year":"2005","unstructured":"Crofford LJ, Rowbotham MC, Mease PJ, Pregabalin 1008\u2013105 Study Group, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264\u201373.","journal-title":"Arthritis Rheum"},{"key":"11_CR16","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jpain.2008.03.013","volume":"9","author":"LM Arnold","year":"2008","unstructured":"Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9:792\u2013805.","journal-title":"J Pain."},{"key":"11_CR17","first-page":"502","volume":"35","author":"PJ Mease","year":"2008","unstructured":"Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35:502\u201314.","journal-title":"J Rheumatol"},{"key":"11_CR18","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.3899\/jrheum.110569","volume":"38","author":"L Pauer","year":"2011","unstructured":"Pauer L, Winkelmann A, Arsenault P, A0081100 Investigators, et al. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol. 2011;38:2643\u201352.","journal-title":"J Rheumatol"},{"key":"11_CR19","doi-asserted-by":"crossref","unstructured":"Nuesch E, Hauser W, Bernardy K, Barth J, Juni P. Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis. 2012 (epub ahead of print).","DOI":"10.1136\/annrheumdis-2011-201249"},{"key":"11_CR20","first-page":"CD008244","volume":"3","author":"S Derry","year":"2012","unstructured":"Derry S, Gill D, Phillips T, Moore RA. Milnacipran for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012;3:CD008244.","journal-title":"Cochrane Database Syst Rev."},{"key":"11_CR21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.semarthrit.2011.06.003","volume":"41","author":"E Choy","year":"2011","unstructured":"Choy E, Marshall D, Gabriel ZL, Mitchell SA, Gylee E, Dakin HA. A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. Semin Arthritis Rheum. 2011;41:335\u2013345.e6.","journal-title":"Semin Arthritis Rheum"},{"key":"11_CR22","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1533-2500.2010.00441.x","volume":"11","author":"NS Roskell","year":"2011","unstructured":"Roskell NS, Beard SM, Zhao Y, Le TK. A meta-analysis of pain response in the treatment of fibromyalgia. Pain Pract. 2011;11:516\u201327.","journal-title":"Pain Pract."},{"key":"11_CR23","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/rheumatology\/keq354","volume":"50","author":"W Hauser","year":"2011","unstructured":"Hauser W, Petzke F, Uceyler N, Sommer C. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology (Oxford). 2011;50:532\u201343.","journal-title":"Rheumatology (Oxford)"},{"key":"11_CR24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1533-2500.2010.00403.x","volume":"11","author":"ME Geisser","year":"2011","unstructured":"Geisser ME, Palmer RH, Gendreau RM, Wang Y, Clauw DJ. A pooled analysis of two randomized, double-blind, placebo-controlled trials of milnacipran monotherapy in the treatment of fibromyalgia. Pain Pract. 2011;11:120\u201331.","journal-title":"Pain Pract."},{"key":"11_CR25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jpain.2010.09.007","volume":"12","author":"AC Siler","year":"2011","unstructured":"Siler AC, Gardner H, Yanit K, Cushman T, McDonagh M. Systematic review of the comparative effectiveness of antiepileptic drugs for fibromyalgia. J Pain. 2011;12:407\u201315.","journal-title":"J Pain."},{"key":"11_CR26","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/AJP.0b013e3181dee80e","volume":"26","author":"LA Bradley","year":"2010","unstructured":"Bradley LA, Wohlreich MM, Wang F, et al. Pain response profile of patients with fibromyalgia treated with duloxetine. Clin J Pain. 2010;26:498\u2013504.","journal-title":"Clin J Pain"},{"key":"11_CR27","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jpain.2010.01.002","volume":"11","author":"W Hauser","year":"2010","unstructured":"Hauser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain. 2010;11:505\u201321.","journal-title":"J Pain."},{"key":"11_CR28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/11202810-000000000-00000","volume":"70","author":"CM Chwieduk","year":"2010","unstructured":"Chwieduk CM, McCormack PL. Milnacipran: in fibromyalgia. Drugs. 2010;70:99\u2013108.","journal-title":"Drugs."},{"key":"11_CR29","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2474-11-150","volume":"11","author":"S Straube","year":"2010","unstructured":"Straube S, Derry S, Moore RA, Paine J, McQuay HJ. Pregabalin in fibromyalgia-responder analysis from individual patient data. BMC Musculoskelet Disord. 2010;11:150.","journal-title":"BMC Musculoskelet Disord."},{"key":"11_CR30","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/rheumatology\/kep432","volume":"49","author":"S Straube","year":"2010","unstructured":"Straube S, Derry S, Moore RA, McQuay HJ. Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology (Oxford). 2010;49:706\u201315.","journal-title":"Rheumatology (Oxford)"},{"key":"11_CR31","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1365-2710.2009.01144.x","volume":"35","author":"TG Tzellos","year":"2010","unstructured":"Tzellos TG, Toulis KA, Goulis DG, et al. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis. J Clin Pharm Ther. 2010;35:639\u201356.","journal-title":"J Clin Pharm Ther"},{"key":"11_CR32","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/jama.2008.944","volume":"301","author":"W Hauser","year":"2009","unstructured":"Hauser W, Bernardy K, Uceyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA. 2009;301:198\u2013209.","journal-title":"JAMA"},{"key":"11_CR33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4088\/PCC.08m00680","volume":"11","author":"LM Arnold","year":"2009","unstructured":"Arnold LM, Clauw DJ, Wohlreich MM, et al. Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebo-controlled clinical trials. Prim Care Companion J Clin Psychiatry. 2009;11:237\u201344.","journal-title":"Prim Care Companion J Clin Psychiatry."},{"key":"11_CR34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pain.2009.05.014","volume":"145","author":"W Hauser","year":"2009","unstructured":"Hauser W, Bernardy K, Uceyler N, Sommer C. Treatment of fibromyalgia syndrome with gabapentin and pregabalin-a meta-analysis of randomized controlled trials. Pain. 2009;145:69\u201381.","journal-title":"Pain"},{"key":"11_CR35","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1089\/jwh.2006.0213","volume":"16","author":"LM Arnold","year":"2007","unstructured":"Arnold LM, Pritchett YL, D\u2019Souza DN, Kajdasz DK, Iyengar S, Wernicke JF. Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials. J Womens Health (Larchmt). 2007;16:1145\u201356.","journal-title":"J Womens Health (Larchmt)."},{"key":"11_CR36","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: L. Erlbaum Associates; 1988.","edition":"2"},{"key":"11_CR37","doi-asserted-by":"crossref","unstructured":"Fitzcharles MA, Ste-Marie PA, Goldenberg DL, et al. 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome. Available at http:\/\/www.canadianpainsociety.ca\/pdf\/Fibromyalgia_Guidelines_2012.pdf . Accessed 16 Jan 2013.","DOI":"10.1155\/2013\/918216"},{"key":"11_CR38","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.mayocp.2012.02.010","volume":"87","author":"LM Arnold","year":"2012","unstructured":"Arnold LM, Clauw DJ, Dunegan LJ, Turk DC. A framework for fibromyalgia management for primary care providers. Mayo Clin Proc. 2012;87:488\u201396.","journal-title":"Mayo Clin Proc"},{"key":"11_CR39","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/ard.2007.071522","volume":"67","author":"SF Carville","year":"2008","unstructured":"Carville SF, Arendt-Nielsen S, Bliddal H, EULAR, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008;67:536\u201341.","journal-title":"Ann Rheum Dis."},{"key":"11_CR40","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.pain.2005.05.001","volume":"116","author":"RA Moore","year":"2005","unstructured":"Moore RA, Edwards JE, McQuay HJ. Acute pain: individual patient meta-analysis shows the impact of different ways of analysing and presenting results. Pain. 2005;116:322\u201331.","journal-title":"Pain."},{"key":"11_CR41","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/ard.2009.107805","volume":"69","author":"RA Moore","year":"2010","unstructured":"Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis. 2010;69:374\u20139.","journal-title":"Ann Rheum Dis."},{"key":"11_CR42","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","volume":"9","author":"RH Dworkin","year":"2008","unstructured":"Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105\u201321.","journal-title":"J Pain."},{"key":"11_CR43","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/acr.20449","volume":"63","author":"PJ Mease","year":"2011","unstructured":"Mease PJ, Spaeth M, Clauw DJ, et al. Estimation of minimum clinically important difference for pain in fibromyalgia. Arthritis Care Res (Hoboken). 2011;63:821\u20136.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"11_CR44","unstructured":"US Food and Drug Administration. Guidance for industry: patient reported outcome measures: use in medical product development to support labeling claims. 2009. Available at http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM193282.pdf . Accessed 13 Mar 2013."},{"key":"11_CR45","unstructured":"European Medicines Agency. Committee for Proprietary Medicinal Products. Points to consider on multiplicity issues in clinical trials. 2002. Available at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003640.pdf . Accessed 13 Mar 2013."},{"key":"11_CR46","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jpainsymman.2005.08.018","volume":"31","author":"JT Farrar","year":"2006","unstructured":"Farrar JT, Dworkin RH, Max MB. Use of the cumulative proportion of responders analysis graph to present pain data over a range of cut-off points: making clinical trial data more understandable. J Pain Symptom Manage. 2006;31:369\u201377.","journal-title":"J Pain Symptom Manage"},{"key":"11_CR47","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1586\/erp.11.12","volume":"11","author":"LD McLeod","year":"2011","unstructured":"McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res. 2011;11:163\u20139.","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"key":"11_CR48","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pec.2008.06.005","volume":"73","author":"LM Arnold","year":"2008","unstructured":"Arnold LM, Crofford LJ, Mease PJ, et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns. 2008;73:114\u201320.","journal-title":"Patient Educ Couns"},{"key":"11_CR49","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/art.33360","volume":"64","author":"LM Arnold","year":"2012","unstructured":"Arnold LM, Williams DA, Hudson JI, et al. Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum. 2012;64:885\u201394.","journal-title":"Arthritis Rheum."},{"key":"11_CR50","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1526-4637.2010.01047.x","volume":"12","author":"LM Arnold","year":"2011","unstructured":"Arnold LM, Zlateva G, Sadosky A, Emir B, Whalen E. Correlations between fibromyalgia symptom and function domains and patient global impression of change: a pooled analysis of three randomized, placebo-controlled trials of pregabalin. Pain Med. 2011;12:260\u20137.","journal-title":"Pain Med."},{"key":"11_CR51","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.3899\/jrheum.090139","volume":"36","author":"JI Hudson","year":"2009","unstructured":"Hudson JI, Arnold LM, Bradley LA, et al. What makes patients with fibromyalgia feel better? Correlations between patient global impression of improvement and changes in clinical symptoms and function: a pooled analysis of 4 randomized placebo-controlled trials of duloxetine. J Rheumatol. 2009;36:2517\u201322.","journal-title":"J Rheumatol."},{"key":"11_CR52","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/1471-2474-12-125","volume":"12","author":"S Straube","year":"2011","unstructured":"Straube S, Moore RA, Paine J, et al. Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response. BMC Musculoskelet Disord. 2011;12:125.","journal-title":"BMC Musculoskelet Disord."},{"key":"11_CR53","first-page":"1130","volume":"35","author":"AJ Busch","year":"2008","unstructured":"Busch AJ, Schachter CL, Overend TJ, Peloso PM, Barber KA. Exercise for fibromyalgia: a systematic review. J Rheumatol. 2008;35:1130\u201344.","journal-title":"J Rheumatol."},{"key":"11_CR54","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/rheumatology\/kep182","volume":"48","author":"J Langhorst","year":"2009","unstructured":"Langhorst J, Musial F, Klose P, Hauser W. Efficacy of hydrotherapy in fibromyalgia syndrome\u2014a meta-analysis of randomized controlled clinical trials. Rheumatology (Oxford). 2009;48:1155\u20139.","journal-title":"Rheumatology (Oxford)."},{"key":"11_CR55","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/ncprheum0245","volume":"2","author":"R Bennett","year":"2006","unstructured":"Bennett R, Nelson D. Cognitive behavioral therapy for fibromyalgia. Nat Clin Pract Rheumatol. 2006;2:416\u201324.","journal-title":"Nat Clin Pract Rheumatol."},{"key":"11_CR56","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/art.24276","volume":"61","author":"W Hauser","year":"2009","unstructured":"Hauser W, Bernardy K, Arnold B, Offenbacher M, Schiltenwolf M. Efficacy of multicomponent treatment in fibromyalgia syndrome: a meta-analysis of randomized controlled clinical trials. Arthritis Rheum. 2009;61:216\u201324.","journal-title":"Arthritis Rheum."}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-013-0011-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T14:41:24Z","timestamp":1562942484000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40122-013-0011-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,18]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["11"],"URL":"https:\/\/doi.org\/10.1007\/s40122-013-0011-1","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,18]]}}}